Although numerous genetic abnormalities, including MYCN amplification, are associated with tumour progression and poor outcome, the molecular mechanisms responsible for the pathogenesis of aggressive neuroblastoma remain unclear. The gene discussed is MYCN; the disease is neuroblastoma.